Acetyl-L-carnitine | CAS#3040-38-8 | α-secretase activity stimulator

MedKoo Cat#: 561871 | Name: Acetyl-L-carnitine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acetyl-L-carnitine is a stimulator of α-secretase activity and metabolism of amyloid precursor protein (APP). It has been shown to induce NF-κB-mediated upregulation of mGluR2 receptors, thereby exhibiting antidepressant, neuroprotective, analgesic, and antinociceptive activities.

Chemical Structure

Acetyl-L-carnitine

CAS#3040-38-8

Theoretical Analysis

MedKoo Cat#: 561871

Name: Acetyl-L-carnitine

CAS#: 3040-38-8

Chemical Formula: C9H17NO4

Exact Mass: 203.1158

Molecular Weight: 203.23

Elemental Analysis: C, 53.19; H, 8.43; N, 6.89; O, 31.49

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Acetyl-L-carnitine; Acetyl L carnitine; ALCAR; L-Acetylcarnitine; L-O-Acetylcarnitine; LAC;

IUPAC/Chemical Name

(3R)-3-Acetyloxy-4-(trimethylazaniumyl)butanoate

InChi Key

RDHQFKQIGNGIED-MRVPVSSYSA-N

InChi Code

InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1

SMILES Code

O=C([O-])C[C@@H](OC(C)=O)C[N+](C)(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 203.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018 Jan 15;9(1):1-24. doi: 10.4239/wjd.v9.i1.1. Review. PubMed PMID: 29359025; PubMed Central PMCID: PMC5763036. 2: Chiechio S, Canonico PL, Grilli M. l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug. Int J Mol Sci. 2017 Dec 21;19(1). pii: E11. doi: 10.3390/ijms19010011. Review. PubMed PMID: 29267192. 3: Phillipson OT. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. Ageing Res Rev. 2017 Nov;40:149-167. doi: 10.1016/j.arr.2017.09.006. Epub 2017 Oct 3. Review. PubMed PMID: 28986235. 4: Sergi G, Pizzato S, Piovesan F, Trevisan C, Veronese N, Manzato E. Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders. Aging Clin Exp Res. 2017 May 22. doi: 10.1007/s40520-017-0770-3. [Epub ahead of print] Review. PubMed PMID: 28534301. 5: Mohammadi M, Hajhossein Talasaz A, Alidoosti M. Preventive effect of l-carnitine and its derivatives on endothelial dysfunction and platelet aggregation. Clin Nutr ESPEN. 2016 Oct;15:1-10. doi: 10.1016/j.clnesp.2016.06.009. Epub 2016 Jun 27. Review. PubMed PMID: 28531771. 6: Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017 May 6;67(3):194-232. doi: 10.3322/caac.21397. Epub 2017 Apr 24. Review. PubMed PMID: 28436999. 7: Chen N, Yang M, Zhou M, Xiao J, Guo J, He L. L-carnitine for cognitive enhancement in people without cognitive impairment. Cochrane Database Syst Rev. 2017 Mar 26;3:CD009374. doi: 10.1002/14651858.CD009374.pub3. Review. PubMed PMID: 28349514. 8: Snyder MJ, Gibbs LM, Lindsay TJ. Treating Painful Diabetic Peripheral Neuropathy: An Update. Am Fam Physician. 2016 Aug 1;94(3):227-34. Review. PubMed PMID: 27479625. 9: Meister R, von Wolff A, Mohr H, Härter M, Nestoriuc Y, Hölzel L, Kriston L. Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PLoS One. 2016 May 17;11(5):e0153380. doi: 10.1371/journal.pone.0153380. eCollection 2016. Review. PubMed PMID: 27187783; PubMed Central PMCID: PMC4871495. 10: Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of Hepatic Encephalopathy: A Primer. Ann Pharmacother. 2016 Jul;50(7):569-77. doi: 10.1177/1060028016645826. Epub 2016 Apr 28. Review. PubMed PMID: 27126547. 11: Traina G. The neurobiology of acetyl-L-carnitine. Front Biosci (Landmark Ed). 2016 Jun 1;21:1314-29. Review. PubMed PMID: 27100509. 12: Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016 Jan 22;14:9. doi: 10.1186/s12916-016-0560-3. Review. PubMed PMID: 26801406; PubMed Central PMCID: PMC4724131. 13: Choi SH, Choi CH. Noise-Induced Neural Degeneration and Therapeutic Effect of Antioxidant Drugs. J Audiol Otol. 2015 Dec;19(3):111-9. doi: 10.7874/jao.2015.19.3.111. Epub 2015 Dec 18. Review. PubMed PMID: 26771008; PubMed Central PMCID: PMC4704551. 14: Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol. 2016 Feb;98:325-34. doi: 10.1016/j.critrevonc.2015.11.014. Epub 2015 Nov 23. Review. PubMed PMID: 26652982; PubMed Central PMCID: PMC4727999. 15: Pessoa BL, Escudeiro G, Nascimento OJ. Emerging Treatments for Neuropathic Pain. Curr Pain Headache Rep. 2015 Dec;19(12):56. doi: 10.1007/s11916-015-0530-z. Review. PubMed PMID: 26530058. 16: Livingstone N, Hanratty J, McShane R, Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. Cochrane Database Syst Rev. 2015 Oct 29;(10):CD011546. doi: 10.1002/14651858.CD011546.pub2. Review. PubMed PMID: 26513128. 17: Onysko M, Legerski P, Potthoff J, Erlandson M. Targeting neuropathic pain: consider these alternatives. J Fam Pract. 2015 Aug;64(8):470-5. Review. PubMed PMID: 26485261. 18: Li S, Laher I. Exercise Pills: At the Starting Line. Trends Pharmacol Sci. 2015 Dec;36(12):906-17. doi: 10.1016/j.tips.2015.08.014. Epub 2015 Oct 2. Review. PubMed PMID: 26439443. 19: Hadera MG, McDonald T, Smeland OB, Meisingset TW, Eloqayli H, Jaradat S, Borges K, Sonnewald U. Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-L-Carnitine. Neurochem Res. 2016 Feb;41(1-2):86-95. doi: 10.1007/s11064-015-1728-5. Epub 2015 Oct 3. Review. PubMed PMID: 26433381. 20: Iozzo P. Metabolic imaging in obesity: underlying mechanisms and consequences in the whole body. Ann N Y Acad Sci. 2015 Sep;1353:21-40. doi: 10.1111/nyas.12880. Epub 2015 Sep 3. Review. PubMed PMID: 26335600.